Back to Signals
🟢 Grant AwardedParis, France
Qubit Pharmaceuticals
Using hybrid quantum-classical computing to accelerate drug discovery through ultra-precise molecular simulations.
Signal Timeline
🟢 Grant Awarded
5 Mar 2026Awarded €4.8M France 2030 DeepTech grant for quantum-enhanced molecular dynamics platform
Qubit Pharma's France 2030 grant is a strong institutional signal. Their hybrid quantum-classical approach is pragmatic — using quantum acceleration where it helps most while leveraging classical compute for the rest. Drug discovery is the most commercially validated use case for quantum computing.
Signal Score
Nucleus Signal Score
Composite score (0–100) across four equal dimensions: Team Strength (25pts), Market Timing (25pts), Deal Velocity (25pts), Signal Quality (25pts). Scores 75+ are tracked as High Conviction.
80
High Conviction